Decipher may help identify ADT benefit in intermediate-risk prostate cancerByAngela Jia, MD, PhDOctober 5th 2026An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.